Synthesis of Radiopharmaceuticals via "In-Loop" 11C-Carbonylation as Exemplified by the Radiolabeling of Inhibitors of Bruton's Tyrosine Kinase.

David J Donnelly, Sean Preshlock, Tanpreet Kaur, Tritin Tran, Thomas C Wilson, Karim Mhanna, Bradford D Henderson, Daniel Batalla, Peter J H Scott, Xia Shao
{"title":"Synthesis of Radiopharmaceuticals <i>via</i> \"In-Loop\" <sup>11</sup>C-Carbonylation as Exemplified by the Radiolabeling of Inhibitors of Bruton's Tyrosine Kinase.","authors":"David J Donnelly, Sean Preshlock, Tanpreet Kaur, Tritin Tran, Thomas C Wilson, Karim Mhanna, Bradford D Henderson, Daniel Batalla, Peter J H Scott, Xia Shao","doi":"10.3389/fnume.2021.820235","DOIUrl":null,"url":null,"abstract":"<p><p>Positron emission tomography (PET) is an important non-invasive tool to help guide the drug discovery and development process. Positron-emitting-radiolabeled drug candidates represent an important tool for drug hunters to gain insight into a drug's biodistribution and target engagement of exploratory biologic targets of interest. Recently, there have been several drug candidates that incorporate an acryloyl functional group due to their ability to form a covalent bond within the biological target of interest through Michael addition. Methods to incorporate a carbon-11 radionuclide into acrylamide derivatives remain challenging given the reactive nature of this moiety. Herein, we report the improved radiosynthesis of carbon-11-containing acrylamide drug candidates, [<sup>11</sup>C]ibrutinib, [<sup>11</sup>C]tolebrutinib, and [<sup>11</sup>C]evobrutinib, using [<sup>11</sup>C]CO and a novel \"in-loop\" <sup>11</sup> <i>C</i>-carbonylation reaction. [<sup>11</sup>C]Ibrutinib, [<sup>11</sup>C]tolebrutinib, and [<sup>11</sup>C]evobrutinib were reliably synthesized, generating 2.2-7.1 GBq of these radiopharmaceuticals in radiochemical yields ranging from 3.3 to 12.8% (non-decay corrected; relative to starting [<sup>11</sup>C]CO<sub>2</sub>) and molar activities of 281-500 GBq/μmol (7.5-13.5 Ci/μmol), respectively. This study highlights an improved method for incorporating carbon-11 into acrylamide drug candidates using [<sup>11</sup>C]CO within an HPLC loop suitable for clinical translation using simple modifications of standard automated synthesis modules used for cGMP manufacture of PET radioligands.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440948/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nuclear medicine (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fnume.2021.820235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Positron emission tomography (PET) is an important non-invasive tool to help guide the drug discovery and development process. Positron-emitting-radiolabeled drug candidates represent an important tool for drug hunters to gain insight into a drug's biodistribution and target engagement of exploratory biologic targets of interest. Recently, there have been several drug candidates that incorporate an acryloyl functional group due to their ability to form a covalent bond within the biological target of interest through Michael addition. Methods to incorporate a carbon-11 radionuclide into acrylamide derivatives remain challenging given the reactive nature of this moiety. Herein, we report the improved radiosynthesis of carbon-11-containing acrylamide drug candidates, [11C]ibrutinib, [11C]tolebrutinib, and [11C]evobrutinib, using [11C]CO and a novel "in-loop" 11 C-carbonylation reaction. [11C]Ibrutinib, [11C]tolebrutinib, and [11C]evobrutinib were reliably synthesized, generating 2.2-7.1 GBq of these radiopharmaceuticals in radiochemical yields ranging from 3.3 to 12.8% (non-decay corrected; relative to starting [11C]CO2) and molar activities of 281-500 GBq/μmol (7.5-13.5 Ci/μmol), respectively. This study highlights an improved method for incorporating carbon-11 into acrylamide drug candidates using [11C]CO within an HPLC loop suitable for clinical translation using simple modifications of standard automated synthesis modules used for cGMP manufacture of PET radioligands.

Bruton酪氨酸激酶抑制剂的放射性标记举例说明通过“In Loop”11C羰基化合成放射性药物
正电子发射断层扫描(PET)是一种重要的非侵入性工具,可以帮助指导药物发现和开发过程。正电子发射放射性标记候选药物是药物猎人了解药物生物分布和探索感兴趣的生物靶标的重要工具。最近,有几种候选药物包含丙烯酰官能团,因为它们能够通过Michael加成在感兴趣的生物靶标内形成共价键。考虑到这部分的反应性,将碳-11放射性核素纳入丙烯酰胺衍生物的方法仍然具有挑战性。在这里,我们报道了使用[11C]CO和一种新的“环内”11C-羰基化反应改进的含碳-11丙烯酰胺候选药物[11C]ibrutinib、[11C]tolebrutinib和[11C]evobrutinib的放射性合成。[11C]Ibrutinib, [11C]tolebrutinib和[11C]evobrutinib被可靠地合成,产生2.2-7.1 GBq这些放射性药物,放射化学产率从3.3到12.8%(未衰变校正;相对于起始[11C]CO2),摩尔活性分别为281 ~ 500 GBq/μmol (7.5 ~ 13.5 Ci/μmol)。本研究强调了一种改进的方法,通过对用于cGMP生产PET放射性配体的标准自动合成模块进行简单修改,在适合临床翻译的HPLC环内使用[11C]CO将碳-11掺入丙烯酰胺候选药物中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信